Pre- and postnatal testosterone administration induces proliferative epithelial lesions with neuroendocrine differentiation in the dorsal lobe of the rat prostate

Prostate

Volumn 40, Issue 2, 1999, Pages 65-75

  Angelsen, Anders ^a,b   Falkmer, Sture ^a   Sandvik, Arne K ^b   Waldum, Helge L ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Neuroendocrine cells; Proliferative lesions; Rat; Testosterone

Indexed keywords

CHROMOGRANIN A; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHLETE; CANCER INCIDENCE; CANCER LOCALIZATION; FEMALE; HISTOPATHOLOGY; IMMUNOREACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TESTOSTERONE BLOOD LEVEL;

AGING; ANIMALS; BODY WEIGHT; CELL DIFFERENTIATION; EPITHELIUM; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY SYSTEMS; ORGAN SIZE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SEXUAL MATURATION; SILVER NITRATE; SILVER STAINING; TESTOSTERONE;

EID: 0033013911     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990701)40:2<65::AID-PROS1>3.0.CO;2-X     Document Type: Article

References (46)

1. National Cancer Institute Prostate Cancer Working Group. National Cancer Institute round table on prostate cancer: future research directions. Cancer Res 1991;51:2498-2505.
2. Bosland MC. The etiopathogenesis of prostatic cancer with special reference to environmental factors. Adv Cancer Res 1988; 51:1-106.
3. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv 1995;25:357-379.
4. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42:3232-3239.
5. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-1933.
6. Pollard MP, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 1982;3:563-568.
7. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991;13:200-227.
8. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
9. Bosland MC, Dreef-van der Meulen HC, Sakumar S, Ofner P, Leav I, Han X, Liehr JG. The role of hormones. In: Harris CC, editor. Multistage carcinogenesis. Tokyo: Japan Scientific Society Press; 1992. p 109-123.
10. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate. Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
11. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1992;23:287-296.
12. Yamada T. Local regulatory actions of gastrointestinal peptides. In: Johnson LR, editor. Physiology of the gastrointestinal tract. New York: Raven Press; 1987. p 131-142.
13. Angelsen A, Mecsei R, Sandvik AC, Waldum HL. Neuroendocrine cells in the prostate of the rat, guinea pig, cat, and dog. Prostate 1997;33:18-25.
14. di Sant'Agnese PA, Davis NS, Chen M, de Mesy Jensen KL. Age-related changes in the neuroendocrine (endocrine-paracrine) cell population and the serotonin content of the guinea pig prostate. Lab Invest 1987;57:729-736.
15. Hanyu S, Iwanaga T, Kano K, Fujita T. Distribution of serotonin-immunoreactive cells in the lower urinary tract of dogs. Am J Anat 1987;180:349-356.
16. Vittoria A, La Mura E, Budetta G, Paino G, Costagliola A, Cecio A. Immunocitochimica delle cellule a 5-HT nel complesso uretro-prostatico di Bubalus buffalus. Atti del 41° Convegno della Societa Italiana di Anatomia, Torino, 1986.
17. Vittoria A, La Mura E, Cocca T, Cecio A. Serotonin-, somatostatin-and chromogranin A-containing cells of the urethroprostatic complex in the sheep. An immunocytochemical and immunofluorescent study. J Anat 1990;171:169-178.
18. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast TH. Do neuroendocrine cells in prostate cancer express androgen receptor? Histochemistry 1993;100:393-398.
19. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potentials effects on male offspring. Br J Cancer 1988;57:216-218.
20. Waynforth HB, Flecknell P, editors. Experimental and surgical technique in the rat, 2nd ed. London: Academic Press; 1992. p 346.
21. Grimelius L. A silver nitrate stain for α-2-cells in human pancreatic islets. Acta Soc Med Ups 1968;73:243-70.
22. Grimelius L, Wilander E. Silver stains in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol 1980;3:3-12.
23. van Breda E, Menheere PPCA, Geurten P, Keizer HA. Steroid drug delivery system in endocrine and metabolic research: evaluation of three models. Horm Metab Res 1995;27:436-437.
24. Bosland MC, Prinsen MK. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by single administration of N-methyl-N-nitrosurea, 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone proionate. Cancer Res 1990;50:691-699.
25. Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR. Morphological and functional heterogeneity in the rat prostatic gland. Biol Reprod 1991;45:308-321.
26. Pour PM, Stepan K. Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine. Cancer Res 1987;47:5699-5706.
27. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996;29:117-134.
28. Parkinson MC. Preneoplastic lesions of the prostate. Histopathology 1995;27:301-311.
29. Ferguson J, Zincke H, Ellison E, Bergstralh E, Bostwick DG. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44:91-95.
30. Waldum HL, Brenna E, Sandvik AK, Syversen U, Falkmer S. Hormones and carcinogenesis. Endocr Rel Cancer 1998;5:1-4.
31. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B, and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones, prohormones and relationship with argyrophil component of secretory granules. Histochemistry 1986;85:19-28.
32. Sakr WA, Haas GP, Cassin B, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385.
33. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin B, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-443.
34. Zondek T, Zondek LH. The fetal and neonatal prostate. In: Goland M, editor. Normal and abnormal growth of the prostate. Springfield, IL: Charles Thomas; 1995. p 5.
35. Price D. Biology of the prostate and related tissues. NCI Monogr 1963;12:1-28.
36. Hayward SW, Baskin LS, Haughney PC, Cuhna AR, Foster BA, Dahiya R, Prins GS, Cunha GR. Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) 1996;155:81-93.
37. Hayward SW, Baskin LS, Haughney PC, Cuhna AR, Foster BA, Dahiya R, Prins GS, Cunha GR. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. Acta Anat (Basel) 1996;155:94-103.
38. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch [A] 1993;423:291-294.
39. Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett ATK, Abrahamsson P-A. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967-1970.
40. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. Pathol Res Pract 1989;185:373-380.
41. Cohen RJ, Glezerson G, Haffejee Z. Neuroendocrine cells - a new prognostic parameter in prostate cancer. Br J Urol 1991;68: 258-262.
42. Krijnen JLM, Bogdanowicz JFAT, Seldenrijk CA, Mulder PGH, van der Kvast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158: 171-174.
43. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-2119.
44. Wenstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27: 683-687.
45. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem [Suppl] 1992;16:89-98.
46. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-metylurea and testosterone. J Natl Cancer Inst 1986;77:583-587.